Ahmad El Khatib
Pulmonary Disease · Sun City West, AZNPI 1942562293
Payments from drug & device makers
Across 97 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$464
- AstraZeneca$267
- Sanofi$173
- Verona Pharma, Inc.$149
- Baxter Healthcare$109
- Viatris Specialty LLC$81
- plus $486 from 13 others
What the payments were for
- Food & beverage$1,69598%
- Education$342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 45 | $464 |
| AstraZeneca | 7 | $267 |
| Sanofi | 8 | $173 |
| Verona Pharma, Inc. | 5 | $149 |
| Baxter Healthcare | 6 | $109 |
| Viatris Specialty LLC | 3 | $81 |
| ZOLL Respicardia, Inc. | 3 | $76 |
| Boehringer Ingelheim | 3 | $57 |
| Amgen | 2 | $56 |
| ANI Pharmaceuticals, Inc. | 2 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Grifols USA, LLC | 1 | $33 |
| Insmed, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $21 |
| Electromed, Inc. | 3 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,729 in reported general payments places this provider in the 40th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 405 | $313,043 |
| XyremSodium Oxybate | 12 | $257,150 |
| Breo ElliptaFluticasone/Vilanterol | 172 | $88,838 |
| Spiriva RespimatTiotropium Bromide | 97 | $51,081 |
| Incruse ElliptaUmeclidinium Bromide | 69 | $30,294 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $19,000 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $11,728 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 66 | $10,044 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $9,776 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $9,668 |
| DuleraMometasone/Formoterol | 12 | $6,840 |
| Budesonide | 20 | $5,798 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $5,434 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 15 | $5,191 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 170 | $4,950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $464 | $454,508690 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $57 | $60,857117 claims |
| AstraZenecaSymbicort | $267 | $9,66832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Sun City West
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Robert OrrPeoria$1.6M
- Sachin ChaudharyTucson$1.2M
- Mark GotfriedPhoenix$1.1M
- George ParidesMesa$913K
- Richard SueGilbert$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.